A Place for Discovery in Biotech--in Which Discovery Knows Its Place
This article was originally published in Start Up
Executive Summary
In a product-oriented world, most biotechs learn to de-emphasize discovery, or even abandon it, in favor of in-licensing-as Vitae appeared to do when it in-licensed a series of molecules from Allergan. But Vitae's recent discovery-stage deal with GlaxoSmithkline, and the follow-on financing that followed it, shows that high-value small-molecule discovery deals can happen and provide valuation increases. But it's the very unusual company that can afford to focus its business entirely on them.
You may also be interested in...
Best of the Blog: START-UP May/June 2009
Our favorite blog posts from May and June related to stories not covered elsewhere in this issue of Start-Up.
Best of the Blog: START-UP May/June 2009
Our favorite blog posts from May and June related to stories not covered elsewhere in this issue of Start-Up.
Best of the IN VIVO Blog, October 2008
Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In October, Windhover's editorial staff posted 36 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. A few of our favorite blog posts include: Lilly's Prasugrel Delay; Glaxo has Seen the Future and the Future is Mouthwash; and FDA Has a New Guard Dog and He's a Wolfe.